Publisher Correction: Molecular predictors of minimal residual disease in newly diagnosed multiple myeloma treated with quadruplet therapy - Takeaways - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Publisher Correction: Molecular factors predicting minimal residual disease in newly diagnosed multiple myeloma treated with quadruplet therapy

  • By

  • Florence Magrangeas

  • Mia Cherkaoui

  • Victor Bessonneau-Gaborit

  • Jennifer Derrien

  • Céline Chevalier

  • Catherine Guérin-Charbonnel

  • Benjamin Diamond

  • Mehmet Kemal Samur

  • Cyrille Hulin

  • Denis Caillot

  • Lionel Karlin

  • Bertrand Arnulf

  • Ola Landgren

  • Nikhil C. Munshi

  • Hervé Avet-Loiseau

  • Ludovic Martinet

  • Jill Corre

  • Aurore Perrot

  • Philippe Moreau

  • Cyrille Touzeau

  • Stéphane Minvielle

  • Eric Letouzé

  • November 3, 2026

Share

  • 1

    A correction to the Nature Medicine article on molecular factors predicting minimal residual disease in newly diagnosed multiple myeloma was published online on October 19, 2026.

  • 2

    The correction concerns the article’s abstract.

  • 3

    The abstract had incomplete wording in its seventh and eighth sentences when the article was first published.

  • 4

    The amended abstract text appears in the HTML version of the article.

  • 5

    The amended abstract text also appears in the PDF version of the article.

Original Source(s)

Publisher Correction: Molecular predictors of minimal residual disease in newly diagnosed multiple myeloma treated with quadruplet therapy

  • by Florence Magrangeas, Mia Cherkaoui, Victor Bessonneau-Gaborit, Jennifer Derrien, Céline Chevalier, Catherine Guérin-Charbonnel, Benjamin Diamond, Mehmet Kemal Samur, Cyrille Hulin, Denis Caillot, Lionel Karlin, Bertrand Arnulf, Ola Landgren, Nikhil C. Munshi, Hervé Avet-Loiseau, Ludovic Martinet, Jill Corre, Aurore Perrot, Philippe Moreau, Cyrille Touzeau, Stéphane Minvielle, Eric Letouzé

  • November 3, 2026

Related Content

Erin Gillaspie, M.D. M.P.H., Joins Baptist Health Herbert Wertheim Cancer Institute as Chief of Thoracic Surgery

Erin Gillaspie, M.D., M.P.H., has joined Baptist Health Herbert Wertheim Cancer Institute and Baptist Health Cancer Care as chief of thoracic surgery.

  • by

  • November 3, 2026

  • 3 min
A precision T-cell therapy stalls treatment-resistant cancers in clinical trial

  • October 23, 2026

Prime Editing Corrects GATA2 Deficiency in Patient Stem Cells

The double-strand break-free approach increased functional GATA2 alleles and improved the engraftment of edited blood stem cells in mice

  • October 21, 2026

  • 3 min